Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Molecular and Cellular Biology

• Publication date

  1991-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/mcb.11.2.1176-1179.1991PMID 1990273PMCID PMC359805
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice

  1989cited by this paper
• Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors.

  1989cited by this paper
• Transgenic mice and oncogenesis.

  1988cited by this paper
• Oncogenes in transgenic mice.

  1988cited by this paper
• The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells

  1988cited by this paper
• Targeted expression of the ras and myc oncogenes in transgenic mice

  1987cited by this paper
• Common sites of viral integration in lymphomas arising in AKXD recombinant inbred mouse strains.

  1987cited by this paper
• Expression of the c-myc oncogene under control of an immunoglobulin enhancer in E mu-myc transgenic mice

  1987cited by this paper
• The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice.

  1986cited by this paper
• Langerhans' cells, veiled cells, and interdigitating cells in the mouse recognized by a monoclonal antibody

  1986cited by this paper
• Evolution of tumours and the impact of molecular oncology

  1985cited by this paper
• The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice

  1985cited by this paper
• Oncogenes amplified in cancer cells.

  1984cited by this paper
• The multistep nature of cancer development.

  1984cited by this paper
• Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes

  1983cited by this paper
• Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene

  1982cited by this paper
• Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses.

  1982cited by this paper
• 5' flanking region of immunoglobulin heavy chain constant region genes displays length heterogeneity in germlines of inbred mouse strains.

  1980cited by this paper
• Mutation selection and the natural history of cancer

  1975cited by this paper

• PIM3 Kinase: A Promising Novel Target in Solid Cancers

  2024cites this paper
• Targeting Pim kinases in hematological cancers: molecular and clinical review

  2023cites this paper
• MYC and therapy resistance in cancer: risks and opportunities

  2022cites this paper
• Targeting PIM Kinases to Improve the Efficacy of Immunotherapy

  2022cites this paper
• Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies

  2021cites this paper
• A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms

  2020cites this paper
• Ferroptosis: Final destination for cancer?

  2020cites this paper
• PIM-1 kinase: a potential biomarker of triple-negative breast cancer

  2019cites this paper
• The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.

  2019cites this paper
• PIM-1 kinase: a potential biomarker of triple-negative breast cancer

  2019cites this paper
• Hispidulin suppresses cell growth and metastasis by targeting PIM1 through JAK2/STAT3 signaling in colorectal cancer

  2018cites this paper
• PIM 1 KINASE IN ENDOTHELIAL CELL PROLIFERATION AND ADHESION

  2018cites this paper
• RETRACTED ARTICLE: Icariin induces apoptosis in acute promyelocytic leukemia by targeting PIM1

  2017cites this paper
• Physcion 8-O-β-glucopyranoside suppresses tumor growth of Hepatocellular carcinoma by downregulating PIM1.

  2017cites this paper
• Identification of cooperating oncogenic lesions in Myc-driven lymphoma

  2017cites this paper
• PIM kinases as therapeutic targets against advanced melanoma

  2016cites this paper
• Insulin receptor substrate 1 is a substrate of the Pim protein kinases

  2016cites this paper
• Notch in cancer and cancer metabolism : six degrees of intracellular turbulence

  2016cites this paper
• Identification of quinones as novel PIM1 kinase inhibitors.

  2016cites this paper
• PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer

  2016cites this paper
• Association of Nuclear PIM1 Expression with Lymph Node Metastasis and Poor Prognosis in Patients with Lung Adenocarcinoma and Squamous Cell Carcinoma

  2016cites this paper
• The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells

  2015cites this paper
• MYC-mediated synthetic lethality for treatment of hematological malignancies.

  2015cites this paper
• PIM kinase (and Akt) biology and signaling in tumors.

  2015cites this paper
• Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas

  2015cites this paper
• PIM Kinases in AML

  2015cites this paper
• Targeting the Pim kinases in multiple myeloma

  2015cites this paper
• Inauhzin(c) Inactivates c-Myc Independently of p53

  2015cites this paper
• Pim kinases in hematological malignancies: where are we now and where are we going?

  2014cites this paper
• Deletion of Pim Kinases Elevates the Cellular Levels of Reactive Oxygen Species and Sensitizes to K-Ras-Induced Cell Killing

  2014cites this paper
• Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms

  2014cites this paper
• Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo

  2014cites this paper
• Exploiting Cell Cycle Pathways in Cancer Therapy: New (and Old) Targets and Potential Strategies

  2014cites this paper
• Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression.

  2014cites this paper
• Etude de la stabilité et des mécanismes d'action de la protéine kinase oncogénique Pim-2 dans la Leucémie Aigüe Myéloïde

  2014cites this paper
• Signaling circuits in early B-cell development.

  2014cites this paper
• Genetic Modeling of PIM Proteins in Cancer: Proviral Tagging and Cooperation with Oncogenes, Tumor Suppressor Genes, and Carcinogens

  2014cites this paper
• PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.

  2014cites this paper
• MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications.

  2014cites this paper
• Ribosomal Proteins L5 and L11 Cooperatively Inactivate c-Myc via RNA-induced Silencing Complex

  2013cites this paper
• Nouveaux carboxamides d'aminothiazole en tant qu'inhibiteurs de kinase

  2013cites this paper
• MYC‐y mice: From tumour initiation to therapeutic targeting of endogenous MYC

  2013cites this paper
• PIM KINASE INHIBITION: SINGLE AGENT AND COMBINATION APPROACHES IN B-CELL LYMPHOMA

  2013cites this paper
• RNAi-based anti-cancer strategies - targeting the proto-oncogene PIM1 and oncogenic miRNAs

  2013cites this paper
• Targeting aberrant kinase activity in myeloid leukaemias

  2013cites this paper
• N- (3-pyridyl)-biarylamides en tant qu'inhibiteurs de kinase

  2013cites this paper
• PIM1 kinase as a target for cancer therapy

  2012cites this paper
• Composés de cyclohexyle tétrasubstitués à titre d'inhibiteurs de kinases

  2012cites this paper
• The proto-oncogene Pim-1 is a target of miR-33a

  2012cites this paper
• Differential Regulation of Androgen Receptor by PIM-1 Kinases via Phosphorylation-dependent Recruitment of Distinct Ubiquitin E3 Ligases*

  2012cites this paper
• PIM 1 kinase as a target for cancer therapy

  2012cites this paper
• Insights from Pim1 structure for anti-cancer drug design

  2012cites this paper
• Pim1 and Myc reversibly transform murine precursor B lymphocytes but not mature B lymphocytes

  2012cites this paper
• In vivo pool-based shRNA screens to identify modulators of disease progression in hematopoietic malignancies

  2012influential citation
• Transcriptional amplification in tumor cells with elevated c-Myc.

  2012cites this paper
• Phosphorylation of the Androgen Receptor by PIM1 in Hormone Refractory Prostate Cancer

  2012cites this paper
• Assessment of therapeutic targets in experimental models of Myc-induced lymphoma

  2011cites this paper
• The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms.

  2011cites this paper
• Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells

  2011cites this paper
• Investigating the role of Bmi-1 in liver growth and function

  2011cites this paper
• Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma

  2011cites this paper
• The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas

  2011cites this paper
• c-Myc induction of programmed cell death may contribute to carcinogenesis

  2011cites this paper
• For better or for worse: the role of Pim oncogenes in tumorigenesis

  2011cites this paper
• Composés éthers cycliques utiles comme inhibiteurs de kinase

  2011cites this paper
• Pim family of protein kinases: Structure, functions, and roles in hematopoietic malignancies

  2011cites this paper
• The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors.

  2011cites this paper
• Roles of Pim‐3, a novel survival kinase, in tumorigenesis

  2011cites this paper
• Insertional Mutagenesis: A Powerful Tool in Cancer Research

  2011cites this paper
• Why target PIM1 for cancer diagnosis and treatment?

  2010cites this paper
• Retroviruses as Tools to Identify Oncogenes and Tumor Suppressor Genes

  2010cites this paper
• Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.

  2010cites this paper
• PIM‐1 kinase expression in adipocytic neoplasms: diagnostic and biological implications

  2010cites this paper
• A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.

  2010cites this paper
• Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.

  2009cites this paper
• UvA-DARE ( Digital Academic Repository ) Characterization of the Myc collaborating oncogenes Bmi 1 and Gfi 1

  2009cites this paper
• Conditional expression and oncogenicity of c‐myc linked to a CD2 gene dominant control region

  2009cites this paper
• Inhibiteurs hétérocycliques de la kinase pim

  2009cites this paper
• A Role for E2F Activities in Determining the Fate of Myc-Induced Lymphomagenesis

  2009cites this paper
• PIM1 Protein Kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells

  2009cites this paper
• Inhibiteurs bicycliques des kinases

  2009cites this paper
• CDC25A: a rebel within the CDC25 phosphatases family?

  2008cites this paper
• The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells*

  2008cites this paper
• 18. Transgenic Animals

  2008cites this paper
• An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies.

  2008cites this paper
• Inhibiteurs de pim kinase et procédés de leur utilisation

  2008cites this paper
• Immunoglobulin gene alterations in the progression of B cell lymphomas

  2008cites this paper
• Elevated Levels of Oncogenic Protein Kinase Pim-1 Induce the p53 Pathway in Cultured Cells and Correlate with Increased Mdm2 in Mantle Cell Lymphoma*

  2008cites this paper
• Molecular pathways in follicular lymphoma

  2007cites this paper
• Negative regulation of Pim-1 protein kinase levels by the B56β subunit of PP2A

  2007cites this paper
• PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation

  2007cites this paper
• Insertional mutagenesis reveals progression genes and checkpoints in MYC/Runx2 lymphomas.

  2007cites this paper
• PIM1-dependent phosphorylation of Histone H3 at Serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation.

  2007cites this paper
• Co-occurrence analysis of insertional mutagenesis data reveals cooperating oncogenes

  2007cites this paper
• KSHV encoded LANA upregulates Pim-1 and is a substrate for its kinase activity.

  2006cites this paper
• Dérivés de pyrrolo [2,3-b]pyridine en tant qu'inhibiteurs de la protéine kinase

  2006cites this paper
• Transgenic mice for Cre‐inducible overexpression of the oncogenes c‐MYC and Pim‐1 in multiple tissues

  2006cites this paper
• Retroviral insertional mutagenesis: past, present and future

  2005cites this paper
• Regulation of Cytokine Signaling

  2005cites this paper
• Overexpression of PIM‐1 is a potential biomarker in prostate carcinoma

  2005cites this paper